First‐in‐Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3655 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Nassr Nassr und 12 weiteren Autor:innen. Beteiligte Einrichtung: Sanofi, Frankfurt, Germany. Hauptthemen laut MEDLINE: Receptors, Tumor Necrosis Factor, Type I, Signal Transduction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
Oral small molecule inhibitors of tumor necrosis factor alpha (TNFα) are emerging as attractive therapeutic agents for the treatment of various autoimmune diseases. Balinatunfib (SAR441566), a novel oral inhibitor of tumor necrosis factor receptor 1 (TNFR1) signaling, changes the configuration of the soluble TNFα (sTNFα) trimer and prevents its heterotrimerization with TNFR1 but not TNFR2, thereby blocking TNFR1 signaling. Herein, we report the results from a first‐in‐human (FIH) study that evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) following single ascending doses (SAD) and multiple ascending doses (MAD) of balinatunfib in healthy male participants. Single (5–600 mg) and multiple (100–600 mg total daily dose for up to 14 days) oral doses of balinatunfib were well‐tolerated in all participants. Consistent PK data were obtained across the studies, with a median t max of 2.5–5 hours, a mean terminal half‐life of 22–30 hours, and a time to steady state of 5–6 days. A supra‐proportional exposure increase was observed in both SAD and MAD studies, which was less pronounced at doses ≥ 180 mg. Food had no relevant effects on the PK characteristics of balinatunfib. As the main PD read‐out, complete TNFα occupancy was shown at all tested time points after the treatment started. Balinatunfib, as the first clinically tested oral TNFR1 signal inhibitor, demonstrated a good safety profile along with favorable PK/PD characteristics that allowed both once and twice daily dosing, confirming a successful preclinical‐to‐clinical translation and guiding dose selection for further clinical efficacy studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sanofi, Frankfurt, Germany.
- Sanofi, Bridgewater, New Jersey, USA.
- Sanofi, Montpellier, France.
- Charité Research Organization, Berlin, Germany.
ORCID-Profile: Nassr Nassr, Faiza Rharbaoui, Dietmar Weitz, Johann Gassenhuber, Markus Rehberg, Markus Kohlmann, Fabienne Schumacher, Amel Lahmar, Andreas Kovar, Laurent Perrin, Frank-Dietrich Wagner, Maria Wiekowski, Mai Anh Nguyen
Förderung
- Sanofi
Zitieren
APA
Nassr, N., Rharbaoui, F., Weitz, D., Gassenhuber, J., Rehberg, M., Kohlmann, M., Schumacher, F., Lahmar, A., Kovar, A., Perrin, L., Wagner, F. D., Wiekowski, M., & Nguyen, M. A. (2025). First‐in‐Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3655
Vancouver
Nassr N, Rharbaoui F, Weitz D, Gassenhuber J, Rehberg M, Kohlmann M, et al. First‐in‐Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3655
BibTeX
@article{Nassr2025,
author = {Nassr, Nassr and Rharbaoui, Faiza and Weitz, Dietmar and Gassenhuber, Johann and Rehberg, Markus and Kohlmann, Markus and Schumacher, Fabienne and Lahmar, Amel and Kovar, Andreas and Perrin, Laurent and Wagner, Frank-Dietrich and Wiekowski, Maria and Nguyen, Mai Anh},
title = {First‐in‐Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3655}
}
EUVIMED